無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪肝炎 (NASH) 治療薬の世界市場:産業分析と将来展望

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)

発行 Koncept Analytics 商品コード 397981
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.73円で換算しております。
Back to Top
非アルコール性脂肪肝炎 (NASH) 治療薬の世界市場:産業分析と将来展望 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)
出版日: 2018年10月26日 ページ情報: 英文 75 Pages
概要

当レポートでは、世界の非アルコール性脂肪肝炎 (NASH) 治療薬の市場について分析し、疾患の概要や主な診断・治療方法、治療薬市場の動向見通し、種類別・地域別の詳細動向、今後の治療薬開発・治験の見込み、主な市場促進・抑制要因、主要企業のプロファイルなどについて調査・推計しております。

第1章 イントロダクション

  • 非アルコール性脂肪肝炎 (NASH)
  • 原因と症状
  • 診断方法
  • 治療方法

第2章 世界の非アルコール性脂肪肝炎 (NASH) 市場

  • 世界のNASH関連市場の予測
  • 世界のNASH関連市場の予測:薬剤クラス別
  • NASH治療用オフラベル医薬品市場の予測

第3章 世界のNASH治療薬市場

  • 世界のNASH治療薬市場の予測
  • 世界のNASH治療薬市場の予測:薬剤クラス別
  • 世界のNASH治療薬市場の予測:地域別
  • 世界のNASH治療薬市場:種類別

第4章 地域別のNASH市場

  • 米国
  • 欧州
  • その他

第5章 市場の力学

  • 成長促進因子
  • 主な動向と発展
  • 課題

第6章 競合情勢

第7章 企業プロファイル

目次

Non-alcoholic Steatohepatitis or NASH is a common term for "silent" liver disease and can result into cirrhosis, in which liver is permanently damaged and after a certain point could lead to death. Currently, no specific medicines for NASH exist, but certain specialty drugs are expected to enter the market in the year 2020.

The global NASH drugs market is expected to witness a lucrative growth due the mounting occurrence of NASH, rising healthcare expenditure, increasing obese patient population, unmet medical needs and sedentary lifestyle. The market is trending with rising pharmaceutical R&D expenditures, development of NASH diagnosis methods and biomarkers, progressing drugs under pipeline and intensifying e-commerce pharmaceutical products sales. However, there are some growth hindering factors in the market including lethargic drug approval process, high treatment cost and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to constantly increasing prevalence of various types of liver disease and the local companies engaged in the manufacturing of NASH drugs.

The report "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Gilead Sciences, Inc., Allergan Plc (Tobira), Intercept Pharmaceuticals, Inc., and Genfit SA are being profiled along with their respective financials and growth strategies.

1. Market Overview

  • 1.1 Introduction
  • 1.2 Causes & Symptoms
  • 1.3 Diagnosis
  • 1.4 Treatment

2. Global NASH Market

  • 2.1 Global NASH Drugs Market Value Forecast
  • 2.2 Global NASH Drugs Market Value Forecast by Drug Class
  • 2.3 Global NASH Off-Label Drugs Market Value Forecast

3. Global NASH Therapeutics Market

  • 3.1 Global NASH Therapeutics Market Value Forecast
  • 3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
    • 3.2.1 Global Obeticholic Acid (OCA) Drug Value Forecast
    • 3.2.2 Global Obeticholic Acid (OCA) Drug Value Forecast by Region
    • 3.2.3 Global Cenicriviroc (CVC) Drug Value Forecast
    • 3.2.4 Global Cenicriviroc (CVC) Drug Value Forecast by Region
    • 3.2.5 Global Elafibranor Drug Value Forecast
    • 3.2.6 Global Aramchol Drug Value Forecast
    • 3.2.7 Global MGL-3196 Drug Value Forecast
    • 3.2.8 Global INN-217 Drug Value Forecast
    • 3.2.9 Global VK2809 Drug Value Forecast
  • 3.3 Global NASH Therapeutics Market Value Forecast by Region

4. Regional NASH Market

  • 4.1 The U.S. NASH Therapeutics Market Value Forecast
  • 4.2 Europe NASH Therapeutics Market Value Forecast
  • 4.3 RoW NASH Therapeutics Market Value Forecast

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Mounting Occurrence of NASH
    • 5.1.2 Rising HealthCare Expenditure
    • 5.1.3 Swelling Obese Patient Population
    • 5.1.4 Accelerating Economic Growth
    • 5.1.5 Unmet Medical Needs
    • 5.1.6 Sedentary Lifestyle
  • 5.2 Key Trends & Development
    • 5.2.1 Rising Pharmaceutical R&D Expenditures
    • 5.2.2 Development of NASH Diagnosis Methods and Biomarkers
    • 5.2.3 Progressing Drugs under Pipeline
    • 5.2.4 Intensifying E-Commerce Pharmaceutical Products Sales
  • 5.3 Challenges
    • 5.3.1 Lethargic Drug Approval Process
    • 5.3.2 High Treatment Cost
    • 5.3.3 Associated Business Risk

6. Competitive Landscape

  • 6.1 Global NASH Drugs Market
    • 6.1.1 Key Players - Revenue Comparison
    • 6.1.2 Key Players - Market Cap Comparison
    • 6.1.3 Key Players - Product Portfolio Comparison

7. Company Profiles

  • 7.1 Gilead Sciences, Inc.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Allergan Plc (Tobira)
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Intercept Pharmaceuticals, Inc.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Genfit SA
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • List of Figures
  • NAFLD Spectrum and Estimated Advancement Risk
  • Potential Phase III NASH Drugs
  • Global NASH Drugs Market Value Forecast (2017-2027)
  • Global NASH Drugs Market Value Forecast by Drug Class (2017/2022/2027)
  • Global NASH Off-Label Drugs Market Value Forecast (2017-2027)
  • Global NASH Therapeutics Market Value Forecast (2020-2027)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2022)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2027)
  • Global Obeticholic Acid (OCA) Drug Value Forecast (2020-2027)
  • Global Obeticholic Acid (OCA) Drug Value Forecast by Region (2027)
  • Global Cenicriviroc (CVC) Drug Value Forecast (2020-2027)
  • Global Cenicriviroc (CVC) Drug Value Forecast by Region (2027)
  • Global Elafibranor Drug Value Forecast (2020-2027)
  • Global Aramchol Drug Value Forecast (2022-2027)
  • Global MGL-3196 Drug Value Forecast (2023-2027)
  • Global INN-217 Drug Value Forecast (2023-2027)
  • Global VK2809 Drug Value Forecast (2023-2027)
  • Global NASH Therapeutics Market Value Forecast by Region (2022)
  • Global NASH Therapeutics Market Value Forecast by Region (2027)
  • The U.S. NASH Therapeutics Market Value Forecast (2022-2027)
  • Europe NASH Therapeutics Market Value Forecast (2022-2027)
  • RoW NASH Therapeutics Market Value Forecast (2022-2027)
  • The U.S. NASH Patient Population (2017-2027)
  • Global HealthCare Expenditure Per Capita (2013-2017)
  • Global Obese Patient Population (2013-2017)
  • Global GDP Per Capita (2013-2017)
  • Global Pharmaceutical R&D Expenditures (2013-2017)
  • Global E-Commerce Pharmaceutical Products Sales (2017-2022)
  • Drugs Approval Process
  • Key Players - Market Cap Comparison (2018)
  • Gilead Sciences Revenues by Business Segments (2017)
  • Gilead Sciences Revenues and Net Income (2013-2017)
  • Gilead Sciences R&D Expenditure (2015-2017)
  • Allergan (Tobira) Net Revenues by Business Segments (2017)
  • Allergan (Tobira) Net Revenues and Net Loss (2013-2017)
  • Allergan (Tobira) R&D Expenditures (2015-2017)
  • Intercept Pharmaceuticals Revenue and Net Loss (2013-2017)
  • Intercept Pharmaceuticals A&P Expenditures (2015-2017)
  • Intercept Pharmaceuticals R&D Expenditures (2015-2017)
  • Genfit Revenues and Net Loss (2013-2017)
  • Genfit R&D Expenditures (2015-2017)

List of Tables

  • NASH Off-Label Therapies (2017)
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
  • Drugs under Development for NASH (2018)
  • NASH Annual Treatment Cost Comparison (2018)
  • Key Players - Revenue Comparison (2017)
  • Key Players - Product Portfolio Comparison (2018)
  • Intercept Pharmaceuticals Product Pipeline (2018)
  • Genfit Product Pipeline (2018)
Back to Top